reslizumab
Trade name: cinqair
Approved
Mar 23, 2016
Reslizumab, sold under the brand names Cinqair and Cinqaero, is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions. — Wikipedia
Clinical trial activity
21 trials · 14 clinical orgs · 1 marketing orgs
Earliest trial started Jun 1, 2001 (NCT00017862)
Timeline
Indications
Approved for
Mechanism of action
- Interleukin-5INHIBITOR
IL5 inhibitor
Approval history
- approvedMar 23, 2016
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
- Multi-specific
- No
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaReslizumab ↗
- NCATS35A26E427H ↗
- ChEMBLCHEMBL2107884 ↗
Also known as
- cep38072
- cep-38072
- cinqaero
- cinqair
- cinqair
- cinqair
- cinquil
- dcp835
- dcp-835
- reslizumab
- reslizumab
- reslizumab
- reslizumab
- reslizumab
- reslizumab
- reslizumab
- reslizumab
- reslizumab
- sch55700
- sch55700
- sch 55700
- sch-55700
- sch-55700
- sch-55700
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04710134 | Phase 4 | Feb 10, 2021 | McMaster University, Teva |
| NCT04183192 | Phase 1 | Jan 31, 2020 | Food and Drug Administration, Spaulding Clinical Research Inc. |
| NCT03074942 | Phase 2 | May 1, 2017 | Hospital Universitario Lucus Augusti, Sociedad Española de Neumología y Cirugía Torácica |
| NCT02947945 | Phase 2 | May 1, 2017 | Teva, University of Colorado, Denver |
| NCT03052725 | Phase 3 | Mar 13, 2017 | Teva |
| NCT02937168 | Phase 4 | Feb 17, 2017 | Teva |
| NCT02799446 | Phase 3 | Jun 1, 2016 | Allergy and Asthma Clinical Research, CSL Behring |
| NCT02559791 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2015 | McMaster University, Teva, University of Western Ontario |
| NCT02501629 | Phase 3 | Sep 1, 2015 | Teva |
| NCT02452190 | Phase 3 | Sep 1, 2015 | PPD, Teva |
| NCT01990443 | Phase 1 | Jun 1, 2013 | Teva |
| NCT01508936 | Phase 3 | Feb 1, 2012 | Teva |
| NCT01290887 | Phase 3 | Jun 1, 2011 | Cephalon, Teva |
| NCT01287039 | Phase 3 | Apr 1, 2011 | Teva |
| NCT01285323 | Phase 3 | Mar 1, 2011 | Teva |
| NCT01270464 | Phase 3 | Feb 1, 2011 | Cephalon, Teva |
| NCT01111305 | Phase 2 | Apr 1, 2010 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00635089 | Phase 3 | Jul 1, 2008 | Cephalon, Ception |
| NCT00587288 | Phase 2 | Apr 1, 2008 | Cephalon, Ception |
| NCT00538434 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2008 | Cephalon, Ception |
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Teva | For profit | 13 | 10 | 4 | 2011 |
| Cephalon | For profit | 5 | 0 | 2 | 2008 |
| Ception | For profit | 3 | 3 | 2 | 2008 |
| McMaster University | Academic/Hospital | 2 | 2 | 2 | 2015 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2001 |
| Allergy and Asthma Clinical Research | Academic/Hospital | 1 | 0 | 1 | 2016 |
| CSL Behring | For profit | 1 | 1 | 1 | 2016 |
| Food and Drug Administration | Government | 1 | 1 | 1 | 2020 |
| Hospital Universitario Lucus Augusti | Academic/Hospital | 1 | 0 | 1 | 2017 |
| PPD | For profit | 1 | 0 | 1 | 2015 |
| Sociedad Española de Neumología y Cirugía Torácica | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Spaulding Clinical Research Inc. | For profit | 1 | 0 | 1 | 2020 |
| University of Colorado, Denver | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Western Ontario | Academic/Hospital | 1 | 0 | 1 | 2015 |